ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0138

Fewer ESKD Dialysis Patients (pts) Reach Antibody (AB) Levels Consistent with Neutralizing Titers When Vaccinated with Ad26.COV2.S Compared with mRNA COVID-19 Vaccines

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Mulhern, Jeffrey, Baystate Medical Center, Baystate Medical Center, Springfield, MA, US, academic/hospital, Springfield, Massachusetts, United States
  • Fadia, Amit, Arizona Kidney Disease and Hypertension Center, Tuscon, Arizona, United States
  • Patel, Ruchir S., Desert Kidney Associates, Casa Grande, Arizona, United States
  • Ficociello, Linda, Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Willetts, Joanna, Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Dahne-Steuber, Ines, Spectra Laboratories, Spectra Laboratories, Milpitas, CA, US, corporate/medsupport, Milpitas, California, United States
  • Mullon, Claudy, Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Delisi, Josephine, Spectra Laboratories, Spectra Laboratories, Milpitas, CA, US, corporate/medsupport, Milpitas, California, United States
  • Johnson, Curtis D., Spectra Laboratories, Spectra Laboratories, Milpitas, CA, US, corporate/medsupport, Milpitas, California, United States
  • Mysayphonh, Chance, Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Anger, Michael S., Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
  • Hymes, Jeffrey L., Fresenius Medical Care, Global Medical Office, Waltham, Massachusetts, United States
Background

The COVID-19 viral vector (VV) vaccine’s single dose and routine storage requirements may be preferred to the mRNA-based vaccine's 2 doses and low temperature storage requirements. We report an interim analysis of a quality improvement project performed at 2 Arizona dialysis clinics comparing the AB response to VV vaccine with mRNA vaccine in ESKD pts.

Methods

Pts received either the VV vaccine (Ad26.COV2.S) administered in the dialysis clinic or mRNA vaccines (BNT162b2, mRNA-1273) administered in the community. AB response was assessed with remnant blood and a semi-quantitative chemiluminescent assay for IgG directed against the receptor binding domain of the SARS-CoV-2 spike antigen. Values >7.0 Index produce plaque reduction neutralization test (PRNT50) titers greater than 1:80 dilution recommended by the FDA standard for measuring neutralizing titer.

Results

AB response was evaluated at an average of 22 days post vaccination (>14 days post Ad26.COV2.S or post 2nd mRNA vaccine). 36/45 pts (80%) who received the VV vaccine failed to develop an AB index >7 after >14 days post vaccine compared to 5/31 pts (16%) who received an mRNA vaccine (84% achieved AB index >7); all 5 pts had no prior COVID-19 history. Of pts receiving the VV vaccine with prior history of COVID-19, 22% of pts had AB index <8 after 14 days post vaccine. 41 pts receiving the VV vaccine had additional AB measurements in the next 14-37 days (ave 26 days after prior measure). In 34 pts with no prior history of COVID-19, 3 pts achieved AB index >7 in the recent sample and had previously been < 1 (n=1) or 1-7 (n=2), bringing the total number with AB > 7 from 2 to 5 (15%). AB levels remained unchanged in pts with a prior history of COVID-19 (n=9). No demographic or laboratory differences were observed.

Conclusion

Our data support the contention that the available VV-based vaccine against the SARS-CoV-2 virus is not effective in producing AB response in most ESKD pts especially when compared to an mRNA counterpart. If AB indices predict immunity and other studies support our findings, alternative vaccination strategies in ESKD pts vaccinated with VV vaccines is needed.

Funding

  • Commercial Support –